Developing a single-dose, intranasal, live-attenuated vaccine against COVID-19

Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.


The COVID-19 pandemic continues to spread in the U.S. and around the world. COVI-VAC is a single-dose, intranasal, live attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology.

Safe and effective live-attenuated vaccines, presenting all target antigens

Target customized oncolytics to treat primary tumors and shrink off-site metastases


RSV hospitalizations among adults 65+ no vaccine

48.8 million

Flu cases in 2017-18, current vaccines <37% effective

1 in 8

US women (about 12%) will develop invasive breast cancer during lifetime.

Our breakthrough approach to live-attenuated virus design

1. Recode

2. Synthesize

3. Transfect

4. Recover

  • January 26, 2021

    Codagenix Secures U.S. Patent for Codon-Deoptimized RSV Vaccine Candidates

    Patent Covers Human Codon-Deoptimized RSV Vaccine Candidates in G and Other RSV Genes

    Full Story
  • January 11, 2021

    Inhaling away the virus: Is the next generation of COVID vaccines on their way?